Ask AI
ProCE Banner Activity

CE

Plotting a Treatment Course for EGFR-Mutated NSCLC: Nursing Considerations and Skill-Based Training for Oncology Nurses and NPs

Video

In this certified on-demand webcast, a certified registered nurse practitioner provides practical strategies for biomarker testing in EGFR-mutated NSCLC and reviews current first- and second-line treatments as well as approaches to prevent associated toxicities.

Nurse Practitioners/Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Released: October 23, 2025

Expiration: April 22, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with non-small-cell lung cancer.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence in the nursing management of patients with non-small-cell lung cancer who are receiving or eligible for EGFR-targeted treatment. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain practical testing for the early detection and identification of actionable EGFR mutations, including interpreting results and implications for treatment planning

  • Differentiate the mechanisms of action of tyrosine kinase inhibitors, bispecific antibodies, and other EGFR-targeted agents approved for EGFR-mutated NSCLC

  • Provide supportive care for patients receiving EGFR-targeted treatment for ​EGFR-mutated NSCLC, taking into account patient-specific considerations and emphasizing strategies to improve outcomes and quality of life

  • Identify and manage treatment-related AEs associated with EGFR-targeted therapies in patients with EGFR-mutated NSCLC, utilizing evidence-based strategies to minimize patient discomfort and optimize therapeutic outcomes

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Catalyst, Janssen, Jazz, Lilly, Merck, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 23, 2025, through April 22, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1, including 1 hour of pharmacotherapy credit. 

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care Continuum (OCN, CBCN, CPHON, AOCNP)*
  • Oncology Nursing Practice (OCN)*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP)*
  • Treatment (OCN, CBCN, AOCNP, CPHON)*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area.  The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) awarded from this course.